TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Active, not recruiting · NCT06001762 · Registry updated 2026-07-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-07-02 | NCT06001762 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Eli Lilly and Company | 370 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Boston Medical Center | Boston | United States | 200 |
| Dana-Farber Cancer Insitute at Londonderry Hospital | Londonderry | United States | 3 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Dana-Farber Cancer Institute at Foxborough | Foxborough | United States | 17 |
| Dana-Farber Cancer Institute at Merrimack Valley | Methuen | United States | 1 |
| Dana-Farber Cancer Institute at Milford | Milford | United States | 2 |
| Dana-Farber Cancer Institute at South Shore | South Weymouth | United States | 1 |
| Dana-Farber Cancer Institute at Steward St. Elizabeth's | Brighton | United States | 2 |
| Eastern Maine Medical Center (Northern Light) | Brewer | United States | 3 |
| New England Cancer Specialists | Scarborough | United States | 12 |
| Stamford Hospital | Stamford | United States | 10 |